TruBridge (TBRG) Competitors

TruBridge (NASDAQ:TBRG) and Enfusion (NYSE:ENFN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

Does the media refer more to TBRG or ENFN?

In the previous week, TruBridge had 3 more articles in the media than Enfusion. MarketBeat recorded 3 mentions for TruBridge and 0 mentions for Enfusion. TruBridge's average media sentiment score of 1.56 beat Enfusion's score of 0.00 indicating that TruBridge is being referred to more favorably in the media.

Company	Overall Sentiment
TruBridge	Very Positive
Enfusion	Neutral

Does the MarketBeat Community prefer TBRG or ENFN?

Enfusion received 1 more outperform votes than TruBridge when rated by MarketBeat users. However, 69.23% of users gave TruBridge an outperform vote while only 19.61% of users gave Enfusion an outperform vote.

Company	Underperform	Outperform
TruBridge	Outperform Votes 9 69.23%	Underperform Votes 4 30.77%
Enfusion	Outperform Votes 10 19.61%	Underperform Votes 41 80.39%

Which has more volatility and risk, TBRG or ENFN?

TruBridge has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Do analysts prefer TBRG or ENFN?

TruBridge currently has a consensus price target of $21.25, indicating a potential downside of 10.60%. Enfusion has a consensus price target of $12.25, indicating a potential upside of 12.91%. Given Enfusion's higher probable upside, analysts clearly believe Enfusion is more favorable than TruBridge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TruBridge	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enfusion	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do insiders and institutionals hold more shares of TBRG or ENFN?

88.6% of TruBridge shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 10.7% of TruBridge shares are owned by insiders. Comparatively, 36.4% of Enfusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has better earnings & valuation, TBRG or ENFN?

Enfusion has lower revenue, but higher earnings than TruBridge. TruBridge is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TruBridge	$345.74M	1.03	-$44.76M	-$1.35	-17.61
Enfusion	$201.61M	6.94	$6.03M	$0.03	361.63

Is TBRG or ENFN more profitable?

Enfusion has a net margin of 1.70% compared to TruBridge's net margin of -17.72%. Enfusion's return on equity of 6.67% beat TruBridge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TruBridge	-17.72%	1.78%	0.78%
Enfusion	1.70%	6.67%	4.86%

Summary

Enfusion beats TruBridge on 11 of the 18 factors compared between the two stocks.